# Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

> **NCT02065557** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 101 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **BIOLOGICAL:** Adalimumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02065557
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-13
- **Primary completion:** 2020-02-07
- **Final completion:** 2020-02-07
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2020-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02065557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02065557, "Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02065557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*